News extra [these stories appear only on the web]

Row breaks out over German funding of short acting diabetes treatment

BMJ 2006; 332 doi: 10.1136/bmj.332.7546.874-c (Published 13 April 2006)
Cite this as: BMJ 2006;332:874.4

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Annette Tuffs
  1. Heidelberg

    The German independent Institute for Quality and Economic Efficiency in Health Care has come under fire from doctors, patients, politicians, and the drugs industry for questioning the use of short acting insulin analogues for late onset (type 2) diabetes. The institute is Germany's equivalent of the National Institute for Health and Clinical Excellence (NICE) in England.

    Following the institute's report, a federal committee has announced that it intends to forbid health insurance companies from paying for costly short acting insulin analogues rather than insulin.

    No other institution in Europe has published recommendations on the use of these drugs, but NICE published recommendations on long acting insulin in December 2002 (www.nice.org.uk/page.aspx?o=43424).

    The …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular